Skip to content

Study · In vitro (cells) · 2012

5 results

Essential role for thymosin β4 in regulating vascular smooth muscle cell development and vessel wall stability.

Rossdeutsch A, Smart N, Dubé KN, Turner M, Riley PR

Circulation research20 Jun 2012Cited by 52 (Europe PMC)

PMID22723298 (opens in a new tab)DOI10.1161/circresaha.111.259846 (opens in a new tab)PepBankPUB-22723298
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In cells, extracellular Tβ4 stimulated differentiation of mesodermal progenitor cells to a mature mural cell phenotype.

    In plain wordsIn cells, thymosin β4 added from outside pushed progenitor cells to become mature vessel wall cells.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseDifferentiation of mesodermal progenitor cells to mural cell phenotype
    Study

    n: not reported in source

    mesodermal progenitor cells
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistic studies revealed that extracellular Tβ4 can stimulate differentiation of mesodermal progenitor cells to a mature mural cell phenotype through activation of the transforming growth factor-beta (TGFβ) pathway and that reduced TGFβ signaling correlates with the severity of hemorrhagic pheno…
  2. 02LabIn vitro (cells)Mechanism

    In cells, extracellular Tβ4 activated the TGFβ pathway in mesodermal progenitor cells.

    In plain wordsIn cells, thymosin β4 added from outside switched on the TGFβ signalling pathway.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseTGFβ pathway activation
    Study

    n: not reported in source

    mesodermal progenitor cells
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistic studies revealed that extracellular Tβ4 can stimulate differentiation of mesodermal progenitor cells to a mature mural cell phenotype through activation of the transforming growth factor-beta (TGFβ) pathway and that reduced TGFβ signaling correlates with the severity of hemorrhagic pheno…

Studies that did not test the peptide alone3

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 03AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Other

    In mice, a proportion of Tβ4-null embryos showed vascular hemorrhage.

    In plain wordsIn mice, some embryos lacking thymosin β4 had bleeding in their blood vessels.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseVascular hemorrhage in Tβ4-null embryos
    Study

    mousen: not reported in source

    global and endothelial-specific Tβ4 loss-of-function mouse embryos
    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    Phenotypic analyses of both global and endothelial-specific loss-of-function Tβ4 mouse models revealed a proportion of Tβ4-null embryos with vascular hemorrhage coincident with a reduction in smooth muscle cell coverage of their developing vessels.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 04AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Other

    In mice, Tβ4-null embryos with hemorrhage had reduced smooth muscle cell coverage of their developing vessels.

    In plain wordsIn mice, embryos lacking thymosin β4 had fewer smooth muscle cells covering their developing blood vessels.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseSmooth muscle cell coverage of developing vessels in Tβ4-null embryos
    Study

    mousen: not reported in source

    global and endothelial-specific Tβ4 loss-of-function mouse embryos
    Outcome group
    Vascular function · Cardiovascular

    Source sentences

    Summary
    Phenotypic analyses of both global and endothelial-specific loss-of-function Tβ4 mouse models revealed a proportion of Tβ4-null embryos with vascular hemorrhage coincident with a reduction in smooth muscle cell coverage of their developing vessels.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 05AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Mechanism

    In Tβ4-null mouse embryos, reduced TGFβ signaling correlated with the severity of the hemorrhagic phenotype.

    In plain wordsIn mice lacking thymosin β4, lower TGFβ signalling was linked to more severe bleeding.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableTGFβ signaling versus hemorrhage severity in Tβ4-null vasculature
    Study

    mousen: not reported in source

    Tβ4-null mouse embryos
    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    Mechanistic studies revealed that extracellular Tβ4 can stimulate differentiation of mesodermal progenitor cells to a mature mural cell phenotype through activation of the transforming growth factor-beta (TGFβ) pathway and that reduced TGFβ signaling correlates with the severity of hemorrhagic pheno…

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.